1 / 58

Hemophilia

Hemophilia. Galila Zaher Consultant Hematologist MRCPath KAUH. Prevalence. World-wide occurs in all racial groups. Few decades ago, children with haemophilia had a significantly reduced life expectancy. Crippled with arthritis &joint deformity

brigit
Download Presentation

Hemophilia

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Hemophilia Galila Zaher Consultant Hematologist MRCPath KAUH

  2. Prevalence • World-wide occurs in all racial groups. • Few decades ago, children with haemophilia had a significantly reduced life expectancy. • Crippled with arthritis &joint deformity • Recent studies : increased life-expectancy • Now :face few limitations. • Normal schools, most jobs are open with full employment and marriage.

  3. Hemophilia Statistics By Country • Country-specific prevalence statistics • Extrapolations of various prevalence rates against the populations • Calculation is automated and does not take into account differences across various countries • May be highly inaccurate and only give a general indication to actual prevalence CureResearch.com

  4. Hemophilia In The Middle East (Extrapolated Statistics)

  5. Hemophilia Prevalence • Saudi Arabia :1,896 patients with Hemophilia • KFSH Riyadh >150 Patients • Department of Hematology Dammam :54patients • KAUH :40 patients • Lack of public awareness • Absence of national registry • Under- diagnosis

  6. Hereditary Coagulation Factor Deficiencies In KFSH Riyadh • Patient number >159 • Hemophilia A:122 patients Hemophilia B:37 patients

  7. Hereditary Coagulation Factor Deficiencies In Eastern Province • In a retrospective analysis 1991-97 • 54 patients • 42 hemophiliacs, 39 hemophilia A , 2 hemophilia B • 5 Saudi patients factor XIII deficiency • 7 patients von Willebrand disease. • Hemophilia B and von Willebrand disease was lower than expected East Mediterr Health J. 1999 Nov;5(6):1188-95.

  8. Hereditary Coagulation Factor Deficiencies In KAUH • In a 5-year retrospective analysis (2000-2005)KAUH • 47 patients age 4-26 years • 40 inherited factor deficiency & 7 have platelets defect • 21 hemophilia A , 9 hemophilia B • 2 patients factor V deficiency, one FVII, FXI, FX & FXII deficiency • 4 patients von Willebrand disease. • von Willebrand disease was lower than expected • Haemophilia B was higher than expected

  9. Hereditary Coagulation Factor Deficiencies In KAUH

  10. Hemophilia Patient Registry In KAUH

  11. Hemophilia Patient Registry In KAUH

  12. Prevalence Of VWD • VWD commonest inherited bleeding disorder • Dammam 7/54 & KAUH 4/40 • Female patients presenting to gynecologist • Under- diagnosis : lack of lab support • VWF is an acute phase reactant

  13. Diagnosis and Management • Base line coagulation screen • Mixing studies • Factor Assay • Inhibitor quantitation • Factor Concentrate • DDAVP & Tranexamic acid • FFPs & Cryoprecipetate

  14. Report On The Universal DataCollection System Centers for Disease Control and Prevention &National Center for Infectious Diseases Atlanta, Georgia

  15. Prevalence Of Hepatitis B Virus Exposure and Vaccination Status

  16. Hepatitis B Virus Infection • The rate of exposure to HBV in congenital bleeding disorders 11.1% Trans R Soc Trop Med Hyg. 1989 Mar-Apr;83(2):256-7 • 22/40 not tested reflecting lack of written protocols • 18/40 tested and were negative reflecting the routine neonatal immunization program started 1990 in SA including HB vaccine

  17. Hepatitis B Virus

  18. HCV Transmission • HCV major cause of virus-induced liver diseases • 1990, anti-HCV of blood donors became mandatory • Incidence of post-transfusion HCV < 1% • Improvements in HCV antibody assays: 1/106 • Hemophilia generated new susceptible populations

  19. Prevalence Of HCV Infection Among Persons With Hemophilia

  20. Hepatitis C Virus Antibodies Saudi Population • HCV is endemic in the Saudi population • Overall frequency of 5.3% • 5 X > reported from Western Europe and USA • Hemophiliacs. Seropositivity rate :78.6% Vox Sang. 1991;60(3):162-4

  21. Hepatitis C Virus

  22. Case 1 • Patient name: M T • Sex: Male 2 years • Diagnosis: Hemophilia A at age of 7 m • Admission date: 3-11-2002 • Lethargy , vomiting & fever for 1 D • Tonic-clonic convulsions for 2 D

  23. History & Examination • On/off painful joint swelling after minor injuries. • Not on regular treatment • Circumcision 6 m ago (FVIII). • Family history of hemophilia A ,thalassemia & SCA • Vitals normal • Neck rigidity • Neurological examination normal • Other systems examination

  24. Investigations •  Hb: 9.2g/dl WBC: 16.5X109 plt:509X109 • PT: 1.2 sec PTT: 69.2 sec • 50/50 immediate mix PTT 40.2 sec • 50/50 post- incubation mix :PTT 80 sec • Factor VIII level 2% • Inhibitor level :50 Bethesda units • CT scan brain : subdural hematoma

  25. Management • Patient was started on factor VIII concentrate 8 hourly • Aiming x 100% x10 D • Neurosurgery consult : observe • Patient was improving clinically 

  26. Management • Patient was started on Malom Protocol • Cyclophosphamide 2 mg/kg/d • Prednisolone 1 mg/kg/d • Factor VIII stat 100 IU/kg Infusion 10 IU/kg/hr x3D

  27. Hospital Course • Repeat  CT scan : resolution of subdural hematoma • Patient was discharged on • - Tegretol 50 mg PO BID • - Cyclophosphamid 25 mg PO OD • - Prednisolone 5 mg PO BID • - F VIII conc 250 IU IV weekly

  28. Follow-Up •  Follow-up in OPD • Inhibitor screen at Nov 2003. No evidence of inhibitors.

  29. Case 2 • 15 y old girl • Referred with history of PR bleeding . • History of salmonella infection. • PMH of ? 2 attacks of DVT (clinical suspicion).

  30. Case Historycont • CBC : Hb 3.5 g/dl PLT 159X109/L. • Isolated prolonged APTT. • Mixing studies :NC. • Factor VIII level 2%. • PRBCs TX , FFP & FVIII concentrate.

  31. Transfer To KAUH • Fresh PR bleeding & heavy menstrual period . • Febrile . • Bruises on anti-cubital fossa .

  32. Investigations • Hb 7.5 g/dl & APTT 118 sec. • Mixing study :immediate & post incubation NC • Factor VIII level 2% & VWF level 80% • Bethesda assay> 500 IU. • LA screen &ACL Ab :negative . • Septic screen : negative. • Serology: HBSAg “R”,HBEAg positive • Family study FVIII level :normal

  33. Admission Course • Upper GIT endoscopy “Hiatus Hernia”. • No blood TX. • Hb level 7.5 9.5 g/dl on iron supplementation.

  34. Incidence • 1/1,000,000 annually. • Males = females. • 5th decade. • IgG 1-4 K or mixed . • Against A2 domain in 48%. • Or C2 domain : FVIII binding to VWF. Haemophilia 1998 Jul;4(4):558-63

  35. Green D & Lechner K: Thrombosis and Haemostasis 45: 200-203 (1981)

  36. Management • Clinical presentation. • Titer of the inhibitor. • Associated medical condition. • Likelihood of spontaneous remission . • Risk of toxicities of therapy . • Cost .

  37. Management • Prednisolone alone without cyclophosphamide • Regular F/U in OPD • Continuous search for underlying cause • CT chest ,abdomen & pelvis every year • Autoimmune profile every 6m • 3 years since diagnosis: Idiopathic Acquired Hemophilia

  38. Dental Extraction • During F/U patient had fractured wisdom tooth for extraction • Patient was admitted prior to extraction • FVII level >1% • Bethesda assay >500IU • Trial of FVIII conc under IVIG, no improvement in FVIII level • Recombinant FVII 90 micg ; No intra-operative nor post-operative bleed • Local fibrin glue to maintain local hemostasis

  39. Case 3 • Patient name : H K • Known sever HA :bloody diarrhea Oct 2001 • Post circumcision bleed • Lf knee swelling post trauma • Family history :HA brother

  40. Follow Up • Intra-muscular hematoma • Wasting of the Rt hand muscles post wrist bleed • Age :3 years :Inhibitor : 50 B IU • Rt knee hemarthrosis limited extension & flexion • Sever tongue bleed which required ICU admission • Inhibitor assay 2BU Low responder

  41. LA is a 35-y male with severe hemophilia • Left knee joint bleed. • Inhibitor titer of 35 BU • known high responder • Failed immune tolerance. • Hepatitis C positive • Difficult venous access.

  42. Available treatment options • High responder • APCCs every 12 to 24 hours • APCCs is a plasma-derived product (Hep C) • An anamnestic response is not a concern since LA has already failed immune tolerance. • Low risk of thromboembolic complications • Recombinant factor VIIa

  43. Its short half-life • Frequent dosing is needed • Difficult venous access :catheter • Higher cost than APCCs. • Porcine factor VIII may be an option.

  44. Porcine factor VIII • Porcine titer to check for x-reactivity • Titer less than 10 BU, porcine factor VIII may be effective. • Mild infusion reactions in 10% of patients. • Inhibitors may develop to the porcine factor. • Porcine factor must be stored frozen.

  45. 2-year-old child with severe HA. • Spontaneous bleed in the right elbow • 2X rFVIII in the last 36 hours. • However, swelling has worsened • rFVIII had been effective for past bleeds.

  46. Inhibitor titer • rFVIIa while waiting for titer results • High doses of rFVIII would be ineffective and may result in higher inhibitor levels. • X-sensitivity to porcine FVIII is unknown. • Early control of bleeding is essential to prevent permanent damage to the joint.

  47. High inhibitor titer (BU=25). • Control bleeding • Immune Tolerance Induction • Early initiation of ITI and a young age are two factors associated with successful ITI. • Daily factor infusions for a prolonged period of time. • rFVIIa for bleeding episodes (to avoid an anamnestic response). • Inhibitor titers monitored every 2 weeks. • ITI may be started when inhibitor titers are less than 5 BU.

  48. Genetic Disorders &Impact On Health Care Delivery • No agreed-upon definitive cure with acceptable risk • Chronic nature requires lifelong medical attention • Expensive supportive and symptomatic therapy • Significant burden on the health care delivery system. el-Hazmi MA East Mediterr Health J. 1999 Nov;5(6):1104-13.

  49. Thank you

  50. Hemophilia working Group in KAUH • Blood bank specialist • Pediatrician • Infectious disease specialist • Orthopedic surgeon • Dentist • Pharmacist • Hemophilia nurse • Social worker • Hematologist

More Related